| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.006 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.007 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.008 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.093 | 0.008 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.097 | 0.009 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.12 | 0.009 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |